SACLAC is an irreversible inhibitor of acid ceramidase (Ki = 97.1 nM) and a derivative of the acid ceramidase inhibitor SABRAC . It decreases levels of sphingosine-1-phosphate (S1P) and increases total ceramide levels in OCI-AML-2 acute myeloid leukemia (AML) cells when used at a concentration of 2.5 µM. SACLAC (10 and 20 µM) induces apoptosis in primary AML cells. It reduces leukemic burden in MV4-11 and U937 AML mouse xenograft models when administered at a dose of 5 mg/kg.